COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Kurome Therapeutics is a preclinical biotech developing combined IRAK1/4 and pan-FLT3 inhibitors targeting adaptive resistance in cancer, initially focused on poor-prognosis AML with expansion to MDS and select solid tumors.
